朱孝峰

职称： 博士、研究员、博士生导师
职务： 华南恶性肿瘤防治全国重点实验室副主任，实验研究部主任、党总支书记
专长： 细胞死亡调控、免疫逃逸与肿瘤靶向治疗

　　2000年在美国乔治城大学癌症中心学习。现为中国抗癌协会抗癌药物专业委员会副主任委员、中国药理学会肿瘤药理专业委员会副主任委员、中国抗癌协会肿瘤精准治疗专业委员会常务委员、中国抗癌协会肿瘤代谢专业委员会常务委员，广东省抗癌协会抗肿瘤药物专业委员会主任委员。《Cancer Communications》、《Advances in Therapy》等杂志编委。主要从事肿瘤细胞死亡调控、免疫逃逸与靶向药物研究。先后承担国家自然科学基金重点项目、专项项目、国家重点研发计划、973计划课题、863计划以及省市科技项目等多项课题。在国际SCI收录杂志发表论文100余篇，代表性通讯作者论文发表于Nat Cell Biol, Nat Commun（4篇）, Autophagy（5篇）, Signal Transduct Target Ther, Clin Cancer Res等。申请新药发明专利十一项。主编人民卫生出版社出版的《信号转导与疾病》和广东科技出版社出版的《肿瘤生物治疗学》等专著。

学科：1） 肿瘤学 2）药理学 3）生物化学与分子生物学

专业特长： 细胞死亡调控、免疫逃逸与肿瘤靶向治疗

研究方向：
　　1. 细胞死亡方式与肿瘤治疗
　　2. 肿瘤免疫逃逸调控机制
　
联系电话：020-87343149;（Fax）：020-87343170，　Email: zhuxf@sysucc.org.cn
通讯地址：广州市东风东路651号　中山大学肿瘤防治中心实验研究部　邮编 510060

教育经历
　　1993年毕业于皖南医学院临床医学专业， 获学士学位
　　1996年毕业于中山医科大学(现中山大学)，获肿瘤学硕士学位
　　2000年毕业于中山医科大学（现中山大学），获肿瘤学博士学位
 
留学经历
　　2000年美国乔治城大学访问学者，从事Bcl2、Her2等小分子抑制剂筛选模型建立、药物筛选及其抗肿瘤作用研究

主要学术成就
　　围绕溶酶体相关的细胞死亡机制（铁死亡/自噬性死亡）及其在肿瘤靶向治疗中的作用开展研究，取得主要学术成绩如下：(1) 发现铁死亡调控的核心机制。通过全基因及激酶筛选发现，PKCβII通过磷酸化ACSL4 Thr328 诱导ACSL4 激活，扩增脂质过氧化来诱导铁死亡，为铁死亡相关的疾病的治疗提供重要的靶标（Nature Cell Biology,2022）；建立了铁死亡诱导剂筛选模型，发现新型铁死亡诱导剂，为新药研究提供实验基础。(2) 阐明了自噬溶酶体途径调控新机制，为将自噬合理应用于肿瘤治疗提供了理论基础：发现Beclin1 翻译后修饰对自噬的调控及其在肿瘤发生发展中的作用（Nature Communications, 2017；Nature Communications, 2015；Autophagy, 2021) ；发现三阴乳腺癌（TNBC）细胞由于自噬能力低致使Tenascin-C 蛋白选择性自噬溶酶体途径降解受阻而表达异常增高，导致TNBC 细胞对T 细胞免疫耐受的重要原因，明确靶向干预Tenascin-C 与T 细胞检查点抑制剂具有协同抗瘤作用，为TNBC 提出新的联合治疗策略（Nature Communications,2020）。发现自噬溶酶体途径可选择性降解糖酵解限速酶HK2，继而发挥抑制肿瘤细胞糖酵解的功能，揭示了在自噬缺陷的肝癌中，靶向糖酵解的抑制剂具有良好应用前景（Autophagy, 2018）。

主持的主要科研项目
　　承担了国家自然科学基金专项项目、重点项目、面上项目、973课题、重点研发计划课题、广东省科技计划项目等。

主要代表性论文:
1.Zhang HL, Hu BX, Li ZL, Du T, Shan JL, Ye ZP, Peng XD, Li X, Huang Y, Zhu XY, Chen YH, Feng GK, Yang D, Deng R*, Zhu XF*. PKCβII phosphorylates ACSL4 to amplify lipid peroxidation for ferroptosis. Nat Cell Biol, 2022, 24 (1):88-98.
2.Yu Y, Peng XD, Qian XJ, Zhang KM, Huang X, Chen YH, Li YT, Feng GK, Zhang HL, Xu XL, Li S, Li X, Mai J, Li ZL, Huang Y, Yang D, Zhou LH, Zhong ZY, and Li JD, Deng R*, Zhu XF*. Fis1 Phosphorylation by Met Promotes Mitochondrial Fission and Hepatocellular Carcinoma Metastasis. Signal Transduct Target Ther, 2021, 6:401.
3.Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, Ni HH, Zhang KM, Mai J, Hu BX, Huang JH, Zhou LH, Yang D, Peng XD, Feng GK, Tang J, Zhu XF*, Deng R*. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021, 12(1):2672. 
4.Li X, Yang KB, Chen W, Mai J, Wu XQ, Sun T, Wu RY, Jiao L, Li DD, Ji J, Zhang HL, Yu Y, Chen YH, Feng GK, Deng R, Li JD*, Zhu XF*. CUL3 (cullin 3)-mediated ubiquitination and degradation of BECN1 (beclin 1) inhibit autophagy and promote tumor progression. Autophagy, 2021,17(12):4323-4340
5.Deng R, Zhang HL, Huang JH, Cai RZ, Wang Y, Chen YH, Hu BX, Ye ZP, Li ZL, Mai J, Huang Y, Li X, Peng XD, Feng GK, Li JD, Tang J*, Zhu XF*. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. Autophagy. 2021, 17(10):3011-3029.
6.Huang Y, Zhang HL, Li ZL, Du T, Chen YH, Wang Y, Ni HH, Zhang KM, Mai J, Hu BX, Huang JH, Zhou LH, Yang D, Peng XD, Feng GK, Tang J, Zhu XF*, Deng R*. FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun. 2021 May 11;12(1):2672. doi: 10.1038/s41467-021-22618-x. 
7.Zhi-Ling Li, Hai-Liang Zhang, Yun Huang, Jun-Hao Huang, Peng Sun, Ning-Ning Zhou, Yu-Hong Chen, Jia Mai, Yan Wang, Yan Yu, Li-Huan Zhou, Xuan Li, Dong Yang, Xiao-Dan Peng, Gong-Kan Feng, Jun Tang, Xiao-Feng Zhu*, Rong Deng*. Autophagy deficiency promotes triple-negative breast cancer resistance to T cell-mediated cytotoxicity by blocking tenascin-C degradation. Nat Commun，2020 Jul 30;11(1):3806. doi: 10.1038/s41467-020-17395-y.
8.Rong Deng, Jun-Hao Huang, Yan Wang, Li-Huan Zhou, Zi-Feng Wang, Bing-Xin Hu, Yu-Hong Chen, Dong Yang, Jia Mai, Zhi-Ling Li, Hai-Liang Zhang, Yun Huang, Xiao-Dan Peng, Gong-Kan Feng, Xiao-Feng Zhu*, Jun Tang*. Disruption of super-enhancer-driven tumor suppressor gene RCAN1.4 expression promotes the malignancy of breast carcinoma. Mol Cancer. 2020 Aug 8;19(1):122. doi: 10.1186/s12943-020-01236-z 
9.Wu RY, Kong PF, Xia LP, Huang Y, Li ZL, Tang YY, Chen YH, Li X, Senthilkumar R, Zhang HL, Sun T, Xu XL, Yu Y, Mai J, Peng XD, Yang D, Zhou LH, Feng GK, Deng R*, Zhu XF*. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Clin Cancer Res, 2019,25(14): 4530-4541. 
10.Mai J, Zhong ZY, Guo GF, Chen XX, Xiang YQ, Li X, Zhang HL, Chen YH, Xu XL, Wu RY, Yu Y, Li ZL, Peng XD, Huang Y, Zhou LH, Feng GK, Guo X, Deng R*, Zhu XF*. Polo-Like Kinase 1 phosphorylates and stabilizes KLF4 to promote tumorigenesis in nasopharyngeal carcinoma. Theranostics, 2019, 9(12):3541-3554
11.Jiao L, Zhang HL, Li DD, Yang KL, Tang J, Li X, Ji J, Yu Y, Wu RY, Ravichandran S, Liu JJ, Feng GK, Chen MS, Zeng YX, Deng R*, Zhu XF*. Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2). Autophagy. 2018;14(4):671-684. 
12.Ji J, Yu Y, Li ZL, Chen MY, Deng R, Huang X, Wang GF, Zhang MX, Yang Q, Ravichandran S, Feng GK, Xu XL, Yang CL, Qiu MZ, Jiao L, Yang D*, Zhu XF*. XIAP Limits Autophagic Degradation of Sox2 and Is A Therapeutic Target in Nasopharyngeal Carcinoma Stem Cells. Theranostics. 2018 Feb 5;8(6):1494-1510
13.Xuan Li, Xiao-Qi Wu, Rong Deng, Dan-Dan Li, Jun Tang, Wen-Dan Chen, Jing-Hong Chen,  Jiao Ji, Lin Jiao, Shan Jiang, Fen Yang, Gong-Kan Feng, Ravichandran Senthilkumar, Fei Yue, Hai-Liang Zhang, Rui-Yan Wu, Yan Yu, Xue-Lian Xu, Jia Mai, Zhi-Ling Li, Xiao-Dan Peng, Yun Huang, Xiang Huang, Ning-Fang Ma, Qian Tao, Yi-Xin Zeng, Xiao-Feng Zhu*. CaMKII-mediated Beclin 1 phosphorylation regulates autophagy that promotes degradation of Id and neuroblastoma cell differentiation. Nat Commun. 2017; 8(1):1159
14.Ting Sun, Xuan Li, Peng Zhang, Wen-Dan Chen, Hai-Liang Zhang, Dan-Dan Li, Rong Deng, Xiao-Jun Qian, Lin Jiao, Jiao Ji, Yuan-Tian Li, Rui-Yan Wu, Yan Yu, Gong-Kan Feng, Xiao-Feng Zhu*. Acetylation of Beclin 1 inhibits autophagosome maturation and promotes tumour growth. Nat Commun. 2015; 6: 7215. 
15.Jing-Hong Chen, Peng Zhang, Wen-Dan Chen, Dan-Dan Li, Rong Deng, Xuan Li, Jiao Ji, Gong-Kan Feng, Yi-Xin Zeng, Jian-Wei Jiang, Xiao-Feng Zhu*. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to topotecan in cancer cells. Autophagy, 2015; 11(2): 239-52
16.Xiao-Yue Zhang, Xiao-Qi Wu, Rong Deng, Ting Sun, Gong-Kan Feng, Xiao-Feng Zhu*. Upregulation of sestrin 2 expression via JNK pathway activation contributes to autophagy induction in cancer cells. Cell Signal. 2013 Jan;25(1):150-8
17.Rong Deng, Fen Yang, Shao-Hua Chang, Jun Tang, Juan Qin, Gong-Kan Feng, Ke Ding, Xiao-Feng Zhu*. DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth. Mol Pharmacol, 2012, 82(2):189-98
18.Jun Tang, Rong Deng, Rong-Zhen Luo, Guo-Ping Shen, Mo-Yan Cai, Zi-Ming Du, Shang Jiang, Ming-Tian Yang, Jian-Hua Fu, Xiao-Feng Zhu*. Low expression of ULK1 is associated with operable breast cancer progression and is an adverse prognostic marker of survival for patients. Breast Cancer Res Treat, 2012, 134(2):549-60
19.Rong Deng, Jun Tang, Jian-Guo Ma, Shu-Peng Chen, Liang-Ping Xia, Wen-Jun Zhou, Dan-Dan Li, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. PKB/Akt promotes DSB repair in cancer cells through upregulating Mre11 expression following ionizing radiation. Oncogene, 2011, 30: 944-55
20.Rong Deng, Jun Tang, Bin-Fen Xie, Gong-Kan Feng, Yue-Han Huang, Zong-Chao Liu, Xiao-Feng Zhu*. SYUNZ-16, a new synthesized alkannin derivative, induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of AKT/FOXO signal pathway. Int J Cancer, 2010, 127(1):220-9
21.Wen-Jun Zhou, Rong Deng, Xiao-Yue Zhang, Gong-Kan Feng, Lian-Quan Gu, Xiao-Feng Zhu*. G-quadruplex ligand SYUIQ-5 induces autophagy by telomere damage and TRF2 delocalization in cancer cells. Mol Cancer Ther, 2009, 8:3203-3213
22.Dan-Dan Li, Lin-Lin Wang, Rong Deng, Jun Tang, Yang Shen, Jin-Feng Guo, Yao Wang, Liang-Ping Xia, Gong-Kan Feng, Quentin Q Liu, Wen-Lin Huang, Yi-Xin Zeng, Xiao-Feng Zhu*. The pivotal role of c-Jun-NH2-terminal kinase-mediated Beclin-1 expression during anticancer agents-induced autophagy in cancer cells. Oncogene, 2009, 28, 886-898. 
23.Rong Deng, Jun Tang, Liang-Ping Xia, Dan-Dan Li, Lin-Lin Wang, Gong-Kan Feng, Yi-Xin Zeng, Xiao-Feng Zhu*. ExcisaninA induces tumor cells apoptosis and suppresses tumor growth through inhibition of PKB/AKT kinase activity and blockade of its signal pathway. Mol Cancer Ther, 2009, 8(4): 873-882. 
24.Jian-nan Liu, Rong Deng, Jin-Feng Guo, Jun-Min Zhou, Gong-Kan Feng, Zhi-Shu Huang, Lian-Quan Gu, Yi-Xin Zeng, Xiao-Feng Zhu*.  Inhibition of myc promoter and telomerase activity and induction of delayed apoptosis by SYUIQ-5, a novel G-quadruplex interactive agent in leukemia cells. Leukemia, 2007, 21(6), 1300-1302
25.Rong Deng, Wenming Li, Zhong Guan, Jun-Min Zhou, Yi Wang, Yu-Ping Mei, Ming-Tao Li, Gong-Kan Feng, Wenlin Huang, Zong-Chao Liu, Yifan Han, Yi-Xin Zeng and Xiao-Feng Zhu*. Acetylcholinesterase expression mediated by c-Jun-NH2-terminal kinase pathway during anticancer drug-induced apoptosis.  Oncogene, 2006, 25(53):7070-7
26.Jun-Min Zhou, Xiao-Feng Zhu*, Yu-Jin Lu, Rong Deng, Zhi-Shu Huang, Yu-Ping Mei, Yi Wang, Wenlin Huang, Zong-Chao Liu, Lian-Quan Gu and Yin-Xin Zeng. Senescence and telomere shortening induced by novel potent G-quadruplex interactive agents, quindoline derivatives, in human cancer cell lines. Oncogene, 2006, 25, 503-511

主编的专著
1）《肿瘤360》，2014，10，凤凰科学技术出版社，（曾益新主编，朱孝峰副主编）
2）《信号转导与疾病》，2012年5月人民卫生出版社出版，(黄文林，朱孝峰主编)
3）《肿瘤生物治疗学》，2005，12，广东科技出版社，(姜文奇，张晓实，朱孝峰，李志铭主编)
4）《肿瘤分子靶向治疗》，2009，5，人民卫生出版社，（黄文林主编，朱孝峰副主编） 
5）《黑色素瘤基础与临床》，2010，11，人民卫生出版社，（张晓实主编，朱孝峰副主编）

申请的专利
1.用于特定型三阴乳腺癌免疫治疗的组合物, 2021.5.5, 中国，CN202110487230.5
2.N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物。2022,4。中国， CN109438365B
3.一种抗肿瘤化合物Chondrosterin J 及其制备方法与运用， 2013.12 ， 中国，201310692093.4。
4.5-噻唑酰胺类化合物及生物学应用，2010.10，中国，2010102651155。
5.Hirsutanols A 在制备抗肿瘤药物中的应用，2009.10，中国，ZL200910037541.0。
6.紫草萘醌类衍生物及其在制备抗癌药物中的应用。中国专利号：ZL02114973.9 
7.脂肪氨基取代喹啉衍生物及其制备方法和制药用途。中国专利号：ZL200310112457.3；国际专利申请号：PCT/CN2004/000175。
8.Houttuyninum compositions and methods for inhibiting the activity of erbB-2 based thereon. 国际专利申请号：PCT/US01/43123。
9.碘化-3，3’-二乙基-9-甲基-硫杂羰花青的抗肿瘤新用途。中国专利申请号：02134263.6。
10.人表皮生长因子受体2酪氨酸激酶抑制剂。 中国专利申请号：200410052496.3
11.一种查尔酮肟及其组合物、制备方法和应用。中国专利号：ZL200510101717.6
 

更新时间：2024年4月24日